TEVA-SITAGLIPTIN MALATE / METFORMIN DIN 02520494
Status: Marketed
Holder: TEVA CANADA LIMITED
Molecule: SITAGLIPTIN (SITAGLIPTIN MALATE)
Available to quote
Health Canada record
| Active ingredient(s) | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BD07 METFORMIN AND SITAGLIPTIN |
| Original market date | 24-Sep-2024 |
| Current status date | 24-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SITAGLIPTIN (SITAGLIPTIN MALATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02508656 | APO-SITAGLIPTIN MALATE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG | Marketed |
| 02508664 | APO-SITAGLIPTIN MALATE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG | Marketed |
| 02508672 | APO-SITAGLIPTIN MALATE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 100 MG | Marketed |
| 02509415 | APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02509423 | APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02509431 | APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02522705 | TEVA-SITAGLIPTIN MALATE | TEVA CANADA LIMITED | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG | Marketed |
| 02522713 | TEVA-SITAGLIPTIN MALATE | TEVA CANADA LIMITED | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG | Marketed |
| 02522721 | TEVA-SITAGLIPTIN MALATE | TEVA CANADA LIMITED | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 100 MG | Marketed |
| 02520508 | TEVA-SITAGLIPTIN MALATE / METFORMIN | TEVA CANADA LIMITED | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02520516 | TEVA-SITAGLIPTIN MALATE / METFORMIN | TEVA CANADA LIMITED | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02534304 | PRO-SITAGLIPTIN MALATE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG | Cancelled Post Market |
| 02534312 | PRO-SITAGLIPTIN MALATE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 100 MG | Cancelled Post Market |
| 02534290 | PRO-SITAGLIPTIN MALATE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG | Cancelled Post Market |
| 02534223 | PRO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Cancelled Post Market |
| 02534231 | PRO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Cancelled Post Market |
| 02534258 | PRO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29828 | 2023-01-05 | Abbreviated New Drug Submission (ANDS) |